Albireo to Host Virtual Investor Commercial Day 2021

Rhea-AI Summary

BOSTON, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma (Nasdaq: ALBO) has announced a virtual Commercial Day for investors scheduled on February 11, from 11:30 AM to 1:00 PM EST. Presentations will cover the company's long-term strategy, market opportunities in rare liver diseases, and commercialization plans for odevixibat, aimed at treating progressive familial intrahepatic cholestasis (PFIC). The event will be led by CEO Ron Cooper and other leaders. Interested parties can join the call using the provided dial-in details or through the company's investor webpage.

BOSTON, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced that it will host a virtual Commercial Day for investors on February 11 from 11:30-1:00pm EST.

Presentations will include an overview of the long-term corporate strategy, the global market opportunity in rare pediatric and adult liver disease, and the global commercialization strategy and launch readiness plans for odevixibat in progressive familial intrahepatic cholestasis (PFIC), an ultra-rare pediatric cholestatic liver disease.

The event will be hosted by Ron Cooper, President and Chief Executive Officer and members of Albireo leadership.

Commercial Day Call Details for Thursday, February 11 from 11:30-1:00pm EST
Domestic: 1-877-407-0792
International: 1-201-689-8263
Conference ID: 13714756
Participant Webcast Link: http://public.viavid.com/index.php?id=142919

The virtual event will also be accessible from the Albireo Media and Investors page ir.albireopharma.com.

About Albireo
Albireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases, and other adult liver diseases and disorders. Albireo’s lead product candidate, odevixibat, is being developed to treat rare pediatric cholestatic liver diseases with Phase 3 pivotal trials in PFIC, Alagille syndrome and biliary atresia. The Company completed IND-enabling studies for new preclinical candidate A3907 this year and plans to advance development in adult liver disease. Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden. The Boston Business Journal named Albireo one of the 2020 Best Places to Work in Massachusetts for the second consecutive year. For more information on Albireo, please visit www.albireopharma.com.

Media & Investor contacts:
Colleen Alabiso, 857-356-3905, colleen.alabiso@albireopharma.com
Hans Vitzthum, LifeSci Advisors, LLC., 617-430-7578

FAQ

What is the date of Albireo Pharma's virtual Commercial Day?

Albireo Pharma's virtual Commercial Day is scheduled for February 11, 2021.

What will be discussed during the Commercial Day hosted by Albireo Pharma?

The discussions will include Albireo's corporate strategy, market opportunities in liver diseases, and commercialization plans for odevixibat.

Who is hosting the Commercial Day event for Albireo Pharma?

The event will be hosted by Ron Cooper, the President and CEO of Albireo Pharma, along with other leadership members.

How can I participate in the Albireo Pharma Commercial Day?

You can participate via phone at 1-877-407-0792 for domestic calls or 1-201-689-8263 for international calls, using the conference ID 13714756.

What is odevixibat being developed for by Albireo Pharma?

Odevixibat is being developed for the treatment of progressive familial intrahepatic cholestasis (PFIC), an ultra-rare pediatric liver disease.